Quotient Ltd (QTNT) Stock

DelistedNasdaq: QTNTQuotient Limited, a commercial-stage diagnostics company, develops, manufactures, commercializes, and sells products for the global transfusion diagnostics market in the United States, France, Japan, and internationally.

0.04
Final close · Mar 3, 2023

QTNT is no longer traded. Quotient was delisted from the Nasdaq in March 2023.

Prices on this page are historical; the last trade was March 3, 2023 at $0.04.

Quotient stock price history

Split-adjusted closes, 2014–2023

QTNT final trading statistics

Final close
$0.04
Final trading day
Mar 3, 2023
Market cap at delisting
$1.34M
Shares outstanding
3.53M
Final 52-week range
$0.03 – $2.39
Avg. volume (final 3 mo.)
1,645,238
All-time high (split-adj.)
$720.00 · Dec 2014
All-time low (split-adj.)
$0.04 · Feb 2023
Return since IPO
-100.0%
Beta
2.19
Book value / share
-$53.62
Price / book
-0.00
Final 52 wk
0.032.39

Quotient earnings per share

Earnings per share

Quotient revenue & net income

RevenueNet income

Quotient annual financials

Quotient Ltd revenue, net income and EPS by fiscal year
Fiscal yearRevenueNet incomeEPS
FY2022$38.51M-$125.1M-$48.00
FY2021$43.38M-$108.5M-$34.72
FY2020$32.66M-$102.8M-$1.45
FY2019$29.13M-$105.4M-$1.95
FY2018$24.73M-$82.3M-$2.04

Last five fiscal years reported before the delisting; fiscal year ending March. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.

About Quotient Ltd

Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, commercializes, and sells products for the global transfusion diagnostics market in the United States, France, Japan, and internationally. The company is developing MosaiQ, a proprietary technology platform, which provides tests for immunohematology, serological disease screening, and molecular disease screening. Its conventional reagent products for blood grouping include antisera products that are used to identify blood group antigens; reagent red blood cells, which enable the identification of blood group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping. The company also offers MosaiQ SDS Microarray that is designed as a serological disease screening microarray comprised assays to detect cytomegalovirus and Syphilis; MosaiQ MDS Microarray that is designed as a molecular disease screening microarray test for donor red cells or source plasma; MosaiQ IH Microarray as a blood grouping microarray; MosaiQ Autoimmune Microarray; MosaiQ COVID-19; and MosaiQ IH3 Microarray. It sells its products to hospitals, donor collection agencies, independent testing laboratories, original equipment manufacturers, and blood banking operation and other diagnostics companies. Quotient Limited was founded in 2007 and is headquartered in Eysins, Switzerland.

Quotient stock FAQ

What happened to Quotient stock?

Quotient stock was delisted from the Nasdaq. Its final close was $0.04 on March 3, 2023.

Is QTNT stock still trading?

No. QTNT was delisted from the Nasdaq in March 2023 and no longer trades on a U.S. exchange.

What was the last price of QTNT stock?

QTNT closed at $0.04 on its final trading day, March 3, 2023, for a market value of about $1.34M.

What were Quotient's revenue and earnings in its last full fiscal year?

Quotient reported revenue of $38.51M and net income of -$125.1M in fiscal 2022, its last full year as a public company.

When did Quotient go public?

Quotient Ltd stock began trading on April 25, 2014.

Healthcare Equipment & Supplies stocks to research

All Healthcare stocks →